SN-38 (7-Ethyl-10-hydroxycamptothecin) CAS: 86639-52-3
SN-38 is a potent camptothecin derivative known for its strong anti-cancer effects. It features a lactone ring, carbonyl group, and tertiary amine, contributing to its powerful inhibition of topoisomerase I, an enzyme crucial for DNA replication and repair. By blocking this enzyme, SN-38 disrupts DNA processes, leading to cancer cell death.
Key Features and Action
- Mechanism: SN-38 inhibits topoisomerase I, causing DNA damage and triggering apoptosis in cancer cells.
- Structure: Contains key functional groups like a lactone ring and carbonyl, enhancing its binding to topoisomerase I.
Applications in Cancer Treatment
- Drug Formulations: Active metabolite of irinotecan, used in colorectal, lung, and ovarian cancer treatments.
- Combination Therapies: Studied alongside other anti-cancer agents to boost effectiveness.
- Targeted Delivery: Integrated into ADCs and advanced drug delivery systems to enhance precision and reduce side effects.
Clinical Impact
SN-38’s potent mechanism makes it a core component of many cancer therapies. Research continues to explore its use in combination treatments and targeted delivery systems, enhancing its role in oncology.
Handling
- Safety: Highly cytotoxic; handle with caution to avoid severe side effects like neutropenia.
- Storage: Keep under proper conditions to maintain effectiveness.
SN-38 remains critical in cancer therapy due to its unique action and ongoing research aimed at expanding its applications.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
